Скачать или смотреть Engineering Viruses To Cure Cancer: The Future Of Immunotherapy

In this powerful episode, host Igor Rafalovich sits down with Bruno Larida, Chief Business Officer at Omios Biologics, to discuss how cutting-edge oncolytic virus therapies are reshaping the future of cancer treatment. From his global journey in biomedical innovation to his mission to help cure cancer, Bruno shares deep insights into the evolution of immunotherapy, AI in biotech, and the role of biomarkers in precision medicine.

Whether you're a biotech founder, investor, or simply passionate about the next frontier in oncology, this episode offers a fascinating look into how technology, data, and purpose come together to fight one of humanity’s biggest challenges.

📌 Topics Covered

• Bruno’s journey from biomedical engineering to biotech leadership
• How oncolytic viruses work and their evolution through history
• What makes Omios Biologics’ third-generation virus unique
• The concept of Ikigai and finding purpose in scientific innovation
• The role of biomarkers in identifying “cold” vs “hot” tumors
• Synergies between oncolytic viruses and immune checkpoint inhibitors
• Using AI and machine learning in drug discovery and clinical trial design
• The promise of TrialGPT and data-driven patient stratification
• How biotech startups can compete with big pharma using generative AI
• Advice for biotech founders on aligning innovation, regulation, and patient impact

💬 If you’re a cancer patient or survivor, Bruno and the Omeos Biologics team want to hear from you — reach out and share your story.

🔗 Connect with Bruno Larida:   / bruno-larida  
• Omios Biologics: https://www.omiosbio.com/
🔗 Connect with Rafael Consulting:   / igor-rafalovich  

👉 Don’t forget to like, subscribe, and share if you enjoyed this episode. Hit the bell 🔔 to get notified about future conversations with biotech leaders and innovators.

#biotechinnovation #cancertreatment #immunotherapy #oncolyticvirus #aiinhealthcare